Oncology · Phase II

Top sponsors

• First People's Hospital 261 programs
• Chinese Academy of 198 programs
• George Institute for 118 programs
• United Therapeutics Europe 112 programs
• Telethon Foundation 91 programs
• Takeda 79 programs
• Regeneron UK 71 programs
• MSD Merck Sharp 63 programs
• Ningbo Cancer Hospital 62 programs
• Anaxis Pharma 57 programs
• AstraZeneca 52 programs
• HOFFMANN-LA ROCHE 50 programs

1. MK-3475-02A

   Merck Sharp and Dohme

   PD-1 refractory melanoma

   phase 2 · small molecule · active

   1 trial →

2. MK-3475-02B

   Merck Sharp and Dohme

   PD-1 refractory melanoma

   phase 2 · small molecule · active

   1 trial →

3. MK-3475-02C

   Merck Sharp and Dohme

   Stage IIIB or IIIC or IIID melanoma

   phase 2 · small molecule · active

   1 trial →

4. MK-3475-02D

   Merck Sharp and Dohme

   Advanced melanoma with brain metastases, PD-1 refractory or PD-1 naive

   phase 2 · small molecule · active

   1 trial →

5. MK-3475-03A

   Merck Sharp and Dohme

   Renal cell carcinoma

   phase 2 · small molecule · active

   1 trial →

6. MK-3475-03B

   Merck Sharp and Dohme

   Renal cell carcinoma

   phase 2 · small molecule · active

   1 trial →

7. MK-3475-03C

   Merck Sharp and Dohme

   Clear cell renal cell carcinoma

   phase 2 · small molecule · active

   1 trial →

8. MK-3475-04B

   Merck Sharp and Dohme

   Advanced Urothelial Carcinoma

   phase 2 · other · active

   1 trial →

9. MK-3475-04C

   Merck Sharp and Dohme

   Advanced Urothelial Carcinoma

   phase 2 · small molecule · active

   1 trial →

10. MK-3475-04D

    Merck Sharp and Dohme

    Urothelial carcinoma

    phase 2 · small molecule · active

    1 trial →

11. MK-3475-06B

    Merck Sharp and Dohme

    Advanced esophageal squamous cell carcinoma

    phase 2 · small molecule · active

    1 trial →

12. MK-3475-06C

    Merck Sharp and Dohme

    Gastroesophageal cancer

    phase 2 · small molecule · active

    1 trial →

13. MK-3475-06D

    Merck Sharp and Dohme

    Gastroesophageal cancer

    phase 2 · small molecule · active

    1 trial →

14. MK-3475-06E

    Merck Sharp and Dohme

    Esophageal squamous cell carcinoma

    phase 2 · small molecule · active

    1 trial →

15. MK-3475-365

    Merck Sharp and Dohme

    Metastatic Castration-Resistant Prostate Cancer

    phase 2 · small molecule · active

    1 trial →

16. MK-3475-495

    Merck Sharp and Dohme

    Stage IV non-small cell lung cancer

    phase 2 · small molecule · active

    1 trial →

17. MK-3475-667

    Merck Sharp and Dohme

    Classical Hodgkin lymphoma in children and young adults

    phase 2 · small molecule · active

    1 trial →

18. MK-3475-B60

    Fondazione Telethon ETS

    Advanced unresectable classic Kaposi sarcoma relapsed and/or refractory to previous standard treatments.

    phase 2 · small molecule · active

    1 trial →

19. MK-3475-B98

    Merck Sharp and Dohme

    Participants with extensive-stage small cell lung cancer

    phase 2 · small molecule · active

    1 trial →

20. MK-3475-B99

    Merck Sharp and Dohme

    First-line treatment of participants with extensive-stage small cell lung cancer

    phase 2 · small molecule · active

    1 trial →

21. MK-3475A

    Merck Sharp and Dohme

    Relapsed or Refractory Classical Hodgkin’s Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)

    phase 2 · small molecule · active

    1 trial →

22. MK-3475A-F11

    Merck Sharp and Dohme

    Melanoma, Renal Cell Carcinoma, Non-small cell lung cancer

    phase 2 · small molecule · active

    1 trial →

23. MK-4830-002

    Merck Sharp and Dohme

    Primary peritoneal cancer/Fallopian tube cancer

    phase 2 · small molecule · active

    1 trial →

24. MK-5684-01A

    Merck Sharp and Dohme

    Metastatic castration resistant prostate cancer (mCRPC)

    phase 2 · small molecule · active

    1 trial →

25. MK-6070-002

    Merck Sharp and Dohme

    Small cell lung cancer

    phase 2 · small molecule · active

    1 trial →

26. MK-7684A-005

    Merck Sharp and Dohme

    Advanced solid tumors

    phase 2 · small molecule · active

    1 trial →

27. MK-7902-009

    Merck Sharp and Dohme

    Recurrent or metastatic squamous cell carcinoma of the head and neck

    phase 2 · small molecule · active

    1 trial →

28. MK-7902-013

    Merck Sharp and Dohme

    Between ages 2 and 21 and have High Grade Glioma (HGG), Rhabdomyosarcoma (RMS), Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (pPNET), or other solid tumor types (except osteosarcoma)

    phase 2 · small molecule · active

    1 trial →

29. MK-9999-01C

    Merck Sharp and Dohme

    Hepatoblastoma, Rhabdomyosarcoma

    phase 2 · small molecule · active

    1 trial →

30. MK-9999-02A

    Merck Sharp and Dohme

    Colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC)

    phase 2 · small molecule · active

    1 trial →

31. MKC-1

    CASI Pharmaceuticals

    Breast Cancer

    phase 2 · small molecule · completed

    1 trial →

32. MKC-1

    CASI Pharmaceuticals

    Pancreatic Cancer

    phase 2 · small molecule · completed

    1 trial →

33. MKC-1

    CASI Pharmaceuticals

    Ovarian Cancer

    phase 2 · small molecule · completed

    1 trial →

34. MKC-1

    CASI Pharmaceuticals

    Advanced Cancer

    phase 2 · small molecule · completed

    2 trials →

35. ML43332

    Hoffmann-La Roche

    Solid tumors

    phase 2 · small molecule · active

    1 trial →

36. MLN0264

    Takeda

    Pancreatic Adenocarcinoma

    phase 2 · small molecule · terminated

    1 trial →

37. MLN0264

    Takeda

    Adenocarcinoma of the Stomach

    phase 2 · small molecule · terminated

    1 trial →

38. MOGAMULIZUMAB

    Ningbo Cancer Hospital

    Cutaneous T-cell lymphoma, a category of cancers of lymphocytes (a type of white blood cells) that primarily involve the skin, Cutaneous T-cell lymphoma (Mycosis Fungoides (MF)) and Sézary Syndrome (SS))

    phase 2 · small molecule · active

    1 trial →

39. MOR208C115

    Incyte

    Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 2 · small molecule · active

    1 trial →

40. MORAb-202-G000-201

    Eisai Co.,

    Solid tumors in 4 tumor types: platinum resistant ovarian cancer, triple-negative breast cancer (TNBC), endometrial cancer (EC), and non-small cell lung cancer adenocarcinoma; NSCLC).

    phase 2 · small molecule · active

    1 trial →

41. MRG003

    Shanghai University of Traditional Chinese Medicine

    Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

    phase 2 · small molecule · active

    1 trial →

42. MRG003 combined with Dalpicicilip

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 · small molecule · active

    1 trial →

43. MRG003 combined with Pucotenlimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma (HNSCC)

    phase 2 · small molecule · active

    1 trial →

44. MRTX1719

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced or Metastatic Non-small Cell Lung Cancer

    phase 2 · small molecule · active

    1 trial →

45. MRx0518

    4D Molecular Therapeutics

    Urothelial Carcinoma

    phase 2 · small molecule · terminated

    1 trial →

46. MRx0518

    4D Molecular Therapeutics

    Oncology

    phase 2 · small molecule · terminated

    1 trial →

47. MS200095-0031

    Merck Sharp and Dohme

    Lung Cancer

    phase 2 · small molecule · active

    1 trial →

48. MS201924_0002

    Merck Sharp and Dohme

    Epithelial ovarian cancer that progressed on prior PARP inhibitor therapy

    phase 2 · small molecule · active

    1 trial →

Frequently asked questions